Lawsuits filed in New Jersey are part of hundreds of complaints against UnitedHealthcare, PBMs, and pharmaceutical giants ...
Right now, Novo stock is trading at a forward price-to-earnings (P/E) multiple of 22.5 -- its lowest level in well over a year. I think now is a terrific opportunity to scoop up shares of Novo on the ...
Catalent is a global contract development and manufacturing organisation headquartered in New Jersey (US). The parties are now free to close the transaction, as well as Novo Nordisk’s subsequent ...
Novo Nordisk’s takeover of Catalent and the Danish firm’s push to launch a new generation of drugs could boost the importance of GLP agonists in 2025, Barclays analysts said ...